Ameriprise’s Travere Therapeutics TVTX Stock Holding History

Ameriprise’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,366	Closed	-$2.12M	–	4226
2025 Q4	$2.12M	Buy	+55,366	New	+$1.8M	﹤0.01%	2968
2025 Q3	–	Sell	-73,661	Closed	-$1.09M	–	4189
2025 Q2	$1.09M	Sell	73,661 -23,619	-24%	-$391K	﹤0.01%	3236
2025 Q1	$1.74M	Sell	97,280 -188,070	-66%	-$3.82M	﹤0.01%	2967
2024 Q4	$4.97M	Buy	285,350 +162,649	+133%	+$2.88M	﹤0.01%	2356
2024 Q3	$1.72M	Sell	122,701 -479,407	-80%	-$4.99M	﹤0.01%	2990
2024 Q2	$4.95M	Buy	602,108 +97,788	+19%	+$659K	﹤0.01%	2324
2024 Q1	$3.89M	Sell	504,320 -51,387	-9%	-$434K	﹤0.01%	2519
2023 Q4	$5M	Buy	555,707 +139,873	+34%	+$1.02M	﹤0.01%	2348
2023 Q3	$3.72M	Buy	415,834 +132,394	+47%	+$1.87M	﹤0.01%	2503
2023 Q2	$4.35M	Sell	283,440 -36,431	-11%	-$663K	﹤0.01%	2449
2023 Q1	$7.19M	Buy	319,871 +90,883	+40%	+$1.93M	﹤0.01%	2042
2022 Q4	$4.82M	Buy	228,988 +37,565	+20%	+$796K	﹤0.01%	2325
2022 Q3	$4.72M	Buy	+191,423	New	+$4.95M	﹤0.01%	2264
2021 Q2	–	Sell	-23,496	Closed	-$587K	–	3968
2021 Q1	$587K	Sell	23,496 -31,817	-58%	-$879K	﹤0.01%	3340
2020 Q4	$1.51M	Sell	55,313 -28,067	-34%	-$655K	﹤0.01%	2910
2020 Q3	$1.54M	Sell	83,380 -1,440	-2%	-$28K	﹤0.01%	2795
2020 Q2	$1.73M	Buy	84,820 +1,377	+2%	+$21.9K	﹤0.01%	2683
2020 Q1	$1.22M	Buy	83,443 +145	+0.2%	+$2.18K	﹤0.01%	2734
2019 Q4	$1.18M	Buy	83,298 +24,579	+42%	+$314K	﹤0.01%	2987
2019 Q3	$680K	Sell	58,719 -43,114	-42%	-$712K	﹤0.01%	3179
2019 Q2	$2.05M	Sell	101,833 -71,645	-41%	-$1.41M	﹤0.01%	2746
2019 Q1	$3.93M	Sell	173,478 -1,701	-1%	-$37.6K	﹤0.01%	2378
2018 Q4	$3.96M	Buy	175,179 +71,371	+69%	+$1.78M	﹤0.01%	2275
2018 Q3	$2.98M	Sell	103,808 -275	-0.3%	-$7.86K	﹤0.01%	2646
2018 Q2	$2.84M	Sell	104,083 -5,722	-5%	-$152K	﹤0.01%	2579
2018 Q1	$2.46M	Sell	109,805 -1,087	-1%	-$25.9K	﹤0.01%	2612
2017 Q4	$2.34M	Buy	110,892 +80,802	+269%	+$1.85M	﹤0.01%	2581
2017 Q3	$749K	Sell	30,090 -430	-1%	-$9.47K	﹤0.01%	3077
2017 Q2	$592K	Buy	30,520 +290	+1%	+$5.26K	﹤0.01%	3170
2017 Q1	$558K	Sell	30,230 -170	-0.6%	-$3.33K	﹤0.01%	3142
2016 Q4	$575K	Buy	30,400 +320	+1%	+$6.54K	﹤0.01%	3224
2016 Q3	$673K	Sell	30,080 -50	-0.2%	-$952	﹤0.01%	3072
2016 Q2	$537K	Buy	+30,130	New	+$488K	﹤0.01%	3135
2015 Q4	–	Sell	-39,380	Closed	-$798K	–	3933
2015 Q3	$798K	Buy	39,380 +4,990	+15%	+$148K	﹤0.01%	3073
2015 Q2	$1.14M	Buy	+34,390	New	+$942K	﹤0.01%	3072

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise's TVTX Position: Q1 2026 in Review

Ameriprise sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 55,366 shares — an estimated $2.12M sold.

Ameriprise first reported a position in TVTX in Q2 2015 and held it in 35 quarters. The position peaked at $7.19M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Ameriprise reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Ameriprise sold 55,366 Travere Therapeutics shares in Q1 2026, an estimated $2.12M.
Ameriprise first reported a position in Travere Therapeutics in Q2 2015 and held it in 35 quarters.
Ameriprise's Travere Therapeutics position peaked at $7.19M in Q1 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.